

General information about company	
	VALIANT LABORATORIES LIMITED
Name of The Company	
BSE Scrip Code	543998
NSE Symbol	VALIANTLAB
MSE Symbol	NOTLISTED
Date of Start of Financial Year	01-04-2024
Date of End of Financial Year	31-03-2025
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2024
Date of End of Reporting Period	30-09-2024
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes



(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II)We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	14-05-2024
Indicate Company website link for updated RPT policy of the Company	https://valiantlabs.in/wp- content/uploads/2025/02/Related-Party- <u>Transactions.pdf</u>



															Additional d only in case t corporate de the listed ent only once, d	the relat posits, a tity/sub	ed party dvance sidiary. ne repor	y transactions s or invest These deta	on relates to ments made ails need to I when such	loans, inter- e or given by be disclosed
Sr	Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty								onies are r party as ne transac	a i	In case any financial indebtedness is incurred to make or give loans, intercorporate deposits, advances or investments									
No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	transaction	Details of other related party transaction	as approved	Remarks on approval by audit committee	Value of transaction during the period	Opening balance	report Closin baland	Nature of ingindebtedness g (loan/ce issuance of debt/ any other etc.)	Details of other	Cost	tTenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interes Rate (%)	t Tenure	Secured/ unsecured	Purpose for which funds will be utilised by the ultimate recipient	Notes
1	Valiant Laboratories Limited	Santosh Vora	Executive Director(MD)	Remuneration			NA	6	0	0									гестрісті	Textual Information
2	Valiant Laboratories Limited	Santosh Vora	Executive Director(MD)	Loan			NA	0	-360.03	-360.0	03									Textual Information
3	Valiant Laboratories Limited	Shantilal Vora	Non- Executive Director	Loan			NA	0	-358.94	-358.9	94									Textual Information
4	Valiant Laboratories Limited	Paresh Shah	Executive Director(CFO	Remuneration			NA	7.5	0	0										Textual Information
5	Valiant	Paresh Shah	Executive	Loan		Director (CFO)	NA	0	-359.43	-359.4	43									Textual Information
6	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Investment		30000	Approved	8408.47	8097.33	16505	5.8									Textual Information



7	Valiant Laboratories Limited	Valiant Advance Science Private Limited	Wholly Owned Subsidiary	Sale of goods or services		200	Approved	1.68	0	1.68							Textual Information
8	Valiant Laboratories Limited	Valiant Advance Science	Wholly Owned Subsidiary	Purchase of goods or services		20000	Approved	329.95	0	329.95			Advance	0	NA	Unsecured For the purpose of business	Textual Information
9	Valiant Laboratories Limited	Valiant Organics Li mi ted	Ultimate Holding Company	Purchase of goods or services		60000	Approved	806.15	-2218.52	-91.81							Textual Information
10	Valiant Laboratories Limited	Valiant Organics Limited	Ultimate Holding Company	Sale of goods or services		5000	Approved	0.59	0	0							Textual Information
	Valiant Laboratories Limited	Dhanvallabh Ventures LLP	Holding Company	Loan			NA	0	-4861.61	-4861.61							Textual Information
12	Valiant Laboratories Limited	Prakta Patil	Company Secretary	Remuneration			NA	6.33	0	0							Textual Information
13	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Deposit received	200	Approved	0	-96.14	-96.14							Textual Information
14	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Purchase of goods or services		700	Approved	96.54	-18.63	-29.51							Textual Information
15	Valiant Laboratories Limited	Limited	Other Related Party	Any other transaction	Received	500	Approved	177	0	0							Textual Information
16	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Other reimbursements	1000	Approved	325.52	0	166.09							Textual Information
17	Valiant Laboratories	The Trust Valiant	Gratuity Trust	Any other transaction	Gratuity Premium		NA	0.04	0	0							Textual Information
18	Valiant Laboratories Limited	Rachi Vora	Promoter Group	Remuneration		25	Approved	7.5	0	0							Textual Information
19	Valiant Advanced Sciences Private Limited	J.B.Singh	Executive Director	Remuneration		25	Approved	7	0	0							Textual Information
	al value of tra ring the repor		<u> </u>						10180.27	<u> </u>				<u> </u>	<u> </u>		<u> </u>



	Text Block
Textual Information(1)	
Textual Information(2)	
Textual Information(3)	
Textual Information(4)	
Textual Information(5)	
Textual Information(6)	
Textual Information(7)	
Textual Information(8)	The said amount is given in advance towards future purchase.
Textual Information(9)	
Textual Information(10)	
Textual Information(11)	
Textual Information(12)	
Textual Information(13)	
Textual Information(14)	
Textual Information(15)	
Textual Information(16)	
Textual Information(17)	
Textual Information(18)	
Textual Information(19)	